Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Aim of this study is to retrospectively review the effectiveness and safety of personalized Gamma Knife radiosurgery (GKRS) for cavernous sinus hemangiomas (CSHs), summarise experience of personalized GKRS treatment for different volume of CSHs. Methods 187 CSHs patients who received personalized GKRS treatment in our center from 2011.1.1 to 2020.12.31 were enrolled in this study and classified into small and medium CSHs (<20 ml), large CSHs (20-40 ml) and giant CSHs (≥40 ml) according to tumor volume. The personalized GKRS treatment strategy included single GKRS and staged GKRS. Tumor shrinkage rate, clinical symptoms response, and complications after GKRS were recorded during follow-up period. Multivariate factors influencing clinical symptoms response were analyzed after personalized GKRS treatment. Results After a mean follow-up duration of 28 months (range 12-124 months), the tumor control rate was 100%, the mean shrinkage rate of CSHs was 93.2% (61.3%-100%) in the last follow-up. Of the 115 patients with preexisting symptoms, 43 (37.5%) patients showed symptom disappearance, 17 (14.7%) patients demonstrated improvement, and 55 (47.8%) patients remained no change. Previous surgical resection of CSHs (OR=0.025, 95% CI 0.007-0.084, P=0.000) was identified to be an independent risk factor for no symptom improvement after GKRS treatment. Conclusions Personalized GKRS is an effective and safe treatment for different volume of CSHs, which is capable of shrinking the tumor, improving symptoms with extremely low incidence of adverse effects and might be considered as the primary treatment strategy for CSHs.
Background Aim of this study is to retrospectively review the effectiveness and safety of personalized Gamma Knife radiosurgery (GKRS) for cavernous sinus hemangiomas (CSHs), summarise experience of personalized GKRS treatment for different volume of CSHs. Methods 187 CSHs patients who received personalized GKRS treatment in our center from 2011.1.1 to 2020.12.31 were enrolled in this study and classified into small and medium CSHs (<20 ml), large CSHs (20-40 ml) and giant CSHs (≥40 ml) according to tumor volume. The personalized GKRS treatment strategy included single GKRS and staged GKRS. Tumor shrinkage rate, clinical symptoms response, and complications after GKRS were recorded during follow-up period. Multivariate factors influencing clinical symptoms response were analyzed after personalized GKRS treatment. Results After a mean follow-up duration of 28 months (range 12-124 months), the tumor control rate was 100%, the mean shrinkage rate of CSHs was 93.2% (61.3%-100%) in the last follow-up. Of the 115 patients with preexisting symptoms, 43 (37.5%) patients showed symptom disappearance, 17 (14.7%) patients demonstrated improvement, and 55 (47.8%) patients remained no change. Previous surgical resection of CSHs (OR=0.025, 95% CI 0.007-0.084, P=0.000) was identified to be an independent risk factor for no symptom improvement after GKRS treatment. Conclusions Personalized GKRS is an effective and safe treatment for different volume of CSHs, which is capable of shrinking the tumor, improving symptoms with extremely low incidence of adverse effects and might be considered as the primary treatment strategy for CSHs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.